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Abstract
Background
Retention in anti-retroviral therapy (ART) presents a challenge in sub-Saharan Africa. In
Mozambique, after roll-out to peripheral facilities, the 12-month retention rate was reported
mostly from sites with an electronic patient tracking system (EPTS), representing only 65%
of patients. We conducted a nationally representative study, compared 12-month retention
at EPTS and non-EPTS sites, and its predictors.
Methods
Applying a proportionate to population size sampling strategy, we obtained a nationally rep-
resentative sample of patients who initiated ART between January 2013 and June 2014. We
calculated weighted proportions of the patients’ status at 12 months after ART initiation, and
12-month incidence of lost to follow-up (LTFU) and death. We assessed determinants of
LTFU and death by calculating adjusted hazard ratios (AHR) through multivariate cox-pro-
portional hazard models.
Results
Among 19,297 patients sampled, 54.3% were still active, 33.1% LTFU, 2.0% dead, 2.6%
transferred-out and 8.0% had unknown status, 12 months after ART initiation. Total attrition
rate (LTFU or dead) was 45.5/100PY, higher at facilities without EPTS (51.8/100PY) than
with EPTS (37.7/100PY). Clinical stage IV (AHR = 1.7), CD4 count150 (AHR = 1.3) and
being pregnant (AHR = 1.6) were significantly associated with LTFU. Clinical stage III or IV
(AHR = 2.1 and 3.8), CD4 count150 (AHR = 3.0), not being pregnant (AHR = 3.0), and
ART regimens with stavudine (AHR = 4.28) were significantly associated with deaths.
Patients enrolled in adherence support groups were 4.6 times less likely to be LTFU, but the
number (n = 174) was too small to be significant (p = 0.273).
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Conclusion
Retention in ART was substantially lower at non-EPTS sites. EPTS should be expanded to
all ART sites to facilitate comprehensive routine monitoring of retention in care. Retention in
Mozambique is low and needs to be improved, especially among pregnant women and
patients with advanced disease at ART initiation. The effect of ART adherence support
groups needs to be further monitored.
Introduction
The delivery of anti-retroviral therapy (ART) has been gradually rolled out in sub-Saharan
Africa over the past decade. UNAIDS estimates that ART coverage in Eastern and Southern
Africa increased from 24% in 2010 to 54% in 2015, reaching a total of 10.3 million people [1].
However, retention in care remains challenging. Several studies and reports have documented
high attrition rates [2–4]. A 2015 review of 123 surveys studying attrition rates in sub-Saharan
Africa estimated the 36-month retention rate to be 65% [5]. Causes of high attrition are multi-
faceted. They include patient-related factors, such as socio-economic and educational levels,
distance living from the ART facility and mobility; health system-related factors, such as pro-
viders’ attitudes, waiting times, drug side effects and defaulter tracking systems; and commu-
nity-level factors, such as level of social and adherence support [6, 7].
Mozambique, a country with an estimated adult HIV prevalence of 12.3% in 2016 [8], has
gradually rolled out ART from hospitals to peripheral and smaller health centres. These
include two types of urban health centres and three types of rural health centres. Urban health
centres A are larger than urban health centres B, but offer mostly the same primary health care
services. The smaller type III rural health centres offer only basic care, type II health centres
have a maternity and type I centres an in-patient department. The number of facilities offering
ART increased from less than 300 in 2011 to 937 in 2016. The number of people on ART
increased to 990,085 by December 2016, corresponding with 54% of those in need [9]. At the
time of our survey, the criteria to initiate ART in adults and children 5 years or older were
WHO clinical stage III or IV, TB co-infection or a CD4 count350 cell/mm3. Children under-
five years of age received universal treatment. The Ministry of Health adopted in 2013 the
Option B+ approach, in which pregnant women are immediately offered HIV treatment for
life regardless of their CD4 count or clinical stage. It was gradually being rolled-out during the
period assessed. In 2015, to enhance retention in care, the country adopted a strategy of ART
adherence support groups, based on a pilot that had shown promising results [10–12]. Reten-
tion in care is not included in the routine monitoring system of the Ministry of Health, and
the country uses the bi-annual indicator generated by the United States President’s Emergency
Plan for AIDS Relief (PEPFAR). This calculates the percentage of patients still active in care 12
months after initiating ART, using the data from the PEPFAR-supported ART facilities. In
December 2014 and 2015 the retention rate reported from these PEPFAR sites was 67% and
66%, respectively [13]. However, facilities not supported by PEPFAR were generally smaller,
more peripheral and without electronic patient tracking system (EPTS), from which the indi-
cator could easily be extracted. EPTS had gradually been introduced by different partners in
Mozambique over the past years, but had not yet achieved full coverage. Facilities with EPTS
represented only about 65% of HIV patients, and the retention rate at non-EPTS facilities was
unknown. At the end of 2014 only 232 of the 795 ART facilities (29%) had an EPTS. With the
exception of some larger PEPFAR-supported ART facilities in the central region of the
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country, non-EPTS facilities are smaller and more remote, and the hypothesis was that attri-
tion is higher. The Ministry of Health and its partners therefore decided to conduct a study
with the objective to estimate 12-month retention in care at non-EPTS sites, compare it to the
retention rate at EPTS sites, and define the national level ART retention rate. To our knowl-
edge, this is the first study conducting such a comparison. In addition, the study assessed fac-
tors associated with attrition, with a particular focus on the effect of recent developments such
as the expansion of Option-B plus and the ART adherence support groups. Attrition rates have
shown to be influenced by these developments and few studies assessed their effect on a
national scale. The findings were compared to those from previous studies in Mozambique to
detect any trends.
Methods
We retrospectively analysed the routinely collected data of a nationally representative sample
of HIV patients who initiated ART between January 1, 2013 and June 30, 2014. For this pur-
pose, we selected 58 facilities applying a two-stage probability proportional to population size
sampling approach, of which 18 had an EPTS and 40 had no EPTS. At the EPTS facilities, we
used the data from the EPTS database. At the non-EPTS facilities, we extracted data from the
paper-based reporting tools, namely ART register books, patient charts, and individual patient
anti-retroviral (ARV) pharmacy refill cards.
The patient’s status 12 months after having initiated ART was established by analysing the
date of initiation, the dates of consultation, the dates of ARV collection, the dates of planned
ARV collection and the recorded outcomes. We classified patient outcomes as ‘dead’, ‘trans-
ferred-out’ or ‘stopped treatment’, if they had this outcome recorded during the 12-month
period, and if the date was consistent with the dates of last consultation and ARV refill. The
Ministry of Health defined stopped treatment as ‘stopped due the following factors: drug toxic-
ity, adverse drug reaction, etc.’. We considered patients as ‘lost to follow-up’ (LTFU) if they
had not been classified as dead, transferred-out or stopped treatment, and had no ARV refill
scheduled within 60 days before or up to 30 days after the end of the 12-month period. At
non-EPTS facilities, we considered all patients who had a consultation recorded within 90
days before the end of the 12 months period as active in care, without consulting the ARV refill
card. We assumed that the patient collected ARV after consultation and had an ARV refill
scheduled 30 days later. Of patients who had no consultation date within 90 days before the
end of the period, we consulted the ARV refill card and checked the scheduled refill date.
Patients for whom it was not possible to retrieve the ARV refill card, and for whom we could
therefore not establish the status with certainty, were classified as ‘status uncertain’. Because at
non-EPTS facilities this occurred frequently, and to enable comparison between EPTS and
non-EPTS facilities, we performed a second round of classification. We considered these
patients active in care if their last consultation was 6 months or less before the end of the
period, and LTFU if it was more than 6 months before the end of the period. Patients for
whom no last consultation and ARV collection dates were available, and patients with incon-
sistent dates were classified as ‘status unknown’. The classification process at non-EPTS sites is
schematically presented in Fig 1.
We compared the characteristics of the sampled facilities with all ART facilities in the coun-
try in terms of province, urban or rural location, type of health facility, and the number of peo-
ple on ART. We then applied weights to adjust for the over and under-representation of these
characteristics. Weighted point estimates for patients who were active in care, had died, were
transferred out, had stopped treatment and were lost to follow-up, 12 months after having ini-
tiated ART, were calculated with their 95% confidence intervals. We used bootstrapping and
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adjusted for the cluster effect in patients assessed at the same facility. To estimate incidence
rates of lost to follow-up and death, the total amount of exposed person-months was calculated
by subtracting the date of initiation of ART from the date of outcome. We used a Poisson
regression model, excluding patients who were transferred out or for whom the status was,
after the final classification, unknown. To assess if lost to follow-up and death were indepen-
dently associated with the collected patient or facility characteristics, we applied a multivariate
cox-proportional hazard model, using jack-knife resampling and controlling for the cluster
effect. We used a forward stepwise approach, adding potential confounding characteristics to
the model and withholding them if they altered the hazard ratio (HR) with more than 5%.
Patients with a missing value for the characteristic were included as a separate category. The
variable EPTS/non-EPTS facility was systematically included in all models. We excluded
patients with an uncertain outcome in this analysis. We used STATA IC 14.0 (StataCorp; Col-
lege Station, TX) for all analyses.
All patient names or other personal identifiers recorded during data collection were
removed and the analysis was conducted on a fully anonymized dataset. The final database
was password protected. The study protocol was approved by the National Committee of Bio-
ethics for Health in Mozambique.
Results
Table 1 presents the characteristics of the 19,297 patients enrolled in ART between January
2013-June 2014 at the 58 sampled facilities, of which 11,227 (58%) had enrolled at facilities
with an EPTS and 8,070 (42%) at a facility without EPTS. Most patients were enrolled at rural
health centres, in particular of type II (38%) and type I (23%), followed by urban health centres
B (18%) and hospitals (15%). The sample did not contain any urban health centre A. Most
Fig 1. Patient outcome classification process at non-EPTS facilities.
https://doi.org/10.1371/journal.pone.0198916.g001
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Table 1. Patient characteristics by EPTS/non-EPTS facility (N = 19,297).
EPTS facilities
(N = 11227)
Non-EPTS facilities
(N = 8070)
Total
(N = 19297)
Characteristic n % n % n %
Type of facility
Rural Health Centre type I 2313 20.6 2150 26.6 4463 23.1
Rural Health Centre type II 2722 24.3 4655 57.7 7377 38.2
Rural Health Centre type III 1074 9.6 0 0.0 1074 5.6
Urban Health Centre type B 3095 27.6 408 5.1 3503 18.2
District Hospital 0 0.0 501 6.2 501 2.6
Rural Hospital 0 0.0 356 4.4 356 1.8
Provincial Hospital 359 3.2 0 0.0 359 1.9
General Hospital 1477 13.2 0 0.0 1477 7.7
Central Hospital 187 1.7 0 0.0 187 1.0
Size of facility (No on ART at the end of 2014)
Less than 400 1602 14.3 2963 36.7 4565 23.7
400–999 2524 22.5 2110 26.2 4634 24.0
1000–1999 2820 25.1 2496 30.9 5316 27.6
2000 or more 4281 38.1 501 6.2 4782 24.8
Age
< = 5 655 5.8 441 5.5 1096 5.7
6–15 340 3.0 139 1.7 479 2.5
16–25 2224 19.8 2072 25.7 4296 22.3
26–35 4279 38.1 2269 28.1 6548 33.9
36–45 2179 19.4 887 11.0 3066 15.9
>45 1548 13.8 476 5.9 2024 10.5
No information 2 0.0 1786 22.1 1788 9.3
Adult/child
Adult (> = 15 years) 10266 91.4 5737 71.1 16003 82.9
Child (<15 years) 959 8.5 549 6.8 1508 7.8
No information 2 0.0 1784 22.1 1786 9.3
Sex
Female 7931 70.6 5979 74.1 1391 72.1
Male 3296 29.4 2091 25.9 5387 27.9
Marital status1 (N = 10266) (N = 5737) (N = 16003)
Married 1195 11.6 1138 19.8 2333 14.6
Living with partner 3173 30.9 1444 25.2 4617 28.9
Single 3854 37.5 1230 21.4 5084 31.8
Widowed/Separated 537 5.2 216 3.8 753 4.7
No information 1507 14.7 1709 29.8 3216 20.1
WHO clinical stage
Stage I 4851 43.2 3172 39.3 8023 41.6
Stage II 1954 17.4 1446 17.9 34 17.6
Stage III 2201 19.6 2221 27.5 4422 22.9
Stage IV 566 5.0 415 5.1 981 5.1
No information 1655 14.7 816 10.1 2471 12.8
CD4 count
<50 601 5.4 292 3.6 893 4.6
50–199 1766 15.7 1210 15.0 2976 15.4
(Continued)
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facilities without EPTS (29/40) were smaller sites with less than 400 patients enrolled, and
patients at facilities with EPTS were therefore more often from large ART sites (38% at facili-
ties with more than 2000 patients on ART at the end of 2014) than patients at non-EPTS sites
(6%). Most patients were adults (83%) and female (72%). The most prevalent age category was
between 26 and 35 years old (34%). Of the adults for whom data were available for marital sta-
tus, 54% were either married or cohabiting. WHO clinical stage data at ART initiation were
available for 87% of patients and CD4 count data for only 58%. Of patients with a recorded
clinical stage, 60% percent were in stage I, and of patients with a CD4 result, 33% had a count
of 350 or more. Approximately one third (32%) of the adult women were pregnant at ART ini-
tiation, and of these 81% were recorded as having initiated under option B+. Six percent were
recorded as being co-infected with tuberculosis. The most common ART regimen initiated
was the first-line treatment for adults and children5 years, 3TC+TDF+EFV (47%). About
Table 1. (Continued)
EPTS facilities
(N = 11227)
Non-EPTS facilities
(N = 8070)
Total
(N = 19297)
Characteristic n % n % n %
200–349 2084 18.6 1537 19.1 3621 18.8
350–499 867 7.7 760 9.4 1627 8.4
> = 500 1033 9.2 1095 13.6 2128 11.0
No information 4876 43.4 3176 39.4 8052 41.7
Pregnant2 (N = 7425) (N = 4333) (N = 11758)
No 5861 78.9 2090 48.2 7951 67.6
Yes 1553 20.9 2170 50.1 3723 31.7
No information 11 0.2 73 1.7 84 0.7
Option B+3 (N = 1556) (N = 2677) (N = 4233)
No 273 17.5 26 1.0 299 7.1
Yes 811 52.1 2630 98.2 3441 81.3
No information 472 30.3 21 0.8 493 11.7
TB infection
No 9707 86.5 7220 89.5 16927 87.7
Yes 660 5.9 415 5.1 1075 5.6
No information 860 7.7 435 5.4 1295 6.7
ART regimen at ART initiation
3TC+TDF+EFV 6463 57.6 2683 33.3 9146 47.4
3TC+AZT+NVP 2960 26.4 3078 38.1 6038 31.3
3TC+AZT+EFV 564 5.0 1498 18.6 2062 10.7
3TC+D4T+NVP 704 6.3 444 5.5 1148 6.0
other 232 2.1 132 1.6 364 1.9
No information 304 2.7 235 2.9 539 2.8
Participated in ART adherence support group
No 11155 99.4 7625 94.5 18780 97.3
Yes 72 0.6 102 1.3 174 0.9
No information 0 0.0 343 4.3 343 1.8
1N = adult
2N = Female patients> = 15 years
3N = Pregnant women
https://doi.org/10.1371/journal.pone.0198916.t001
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one third (31%) was initiated with the other adult first-line treatment, and first-line treatment
in children under-five, 3TC+AZT+NVP, and 11% with 3TC+AZT+EFV, the alternative given
in case of renal insufficiency or diabetes. Only 174 patients (0.9%) had participated in an ART
adherence support group.
We could establish with certainty the status 12 months after ART initiation for almost all
patients from EPTS facilities (99.0%), but for only 65% of patients at non-EPTS facilities. The
2,935 patients with an uncertain status were relatively more often from rural health centres
type II (66.1%) than those with certain status (33.2%), but had otherwise similar characteris-
tics. Based on the criteria described above, we classified 1,541 of the patients with an uncertain
status as lost to follow-up, and 261 patients as active in care, leaving 1,133 patients (6%) with-
out sufficient information classified as ‘unknown status’.
Table 2 presents the proportions of the patients’ status 12 months after ART initiation,
weighted for facility characteristics. In the final classification, slightly more than half of the
patients (54%) were confirmed to have been still active in care, 2.6% were transferred out,
2.0% had died, 33% were lost to follow-up (LTFU) and for 8% the status was unknown. No
patient was recorded as having stopped treatment. Excluding patients whose status was
unknown or were transferred out, this translated into a death rate of 2.6/100PY and a LTFU
rate of 42.9/100PY, and thus a total attrition rate ((LTFU or dead) of 45.5/100PY (Table 3).
Attrition was substantially higher at non-EPTS sites (51.8/100PY), than at EPTS sites (37.7/
100PY).
Table 4 and Table 5 present the results of the multivariate analysis, applying a cox-propor-
tional hazard model, assessing determinants of LTFU and death. After adjusting for the con-
founding effect of other available determinants, being pregnant was still significantly (p<0.05)
Table 2. Patients’ status 12 months after ART initiation by type of facility (N = 19,927).
Status EPTS facilities
(N = 11227)
Non-EPTS facilities
(N = 8070)
Total
(N = 19297)
Weighted % 95% CI Weighted % 95% CI Weighted % 95% CI
Initial classification
Active 64.7 56.4–73.0 44.0 39.7–48.3 52.8 41.8–63.7
Lost to follow-up 27.0 22.7–31.3 22.1 17.3–27.0 24.2 21.8–26.6
Death 3.5 1.3–5.7 0.9 0.0–2.6 2.0 0.4–3.6
Transferred out 4.0 0.9–7.1 1.6 0.2–2.9 2.6 0.9–4.2
Uncertain outcome 1.0 0.0–2.0 31.4 27.3–35.5 18.5 5.2–32.8
Final classification
Active 64.7 56.4–73.0 46.7 42.2–51.2 54.3 44.2–64.4
Lost to follow-up 27.2 22.9–31.4 37.5 30.6–44.4 33.1 26.1–40.1
Death 3.5 1.3–5.7 0.9 0.0–2.6 2.0 0.4–3.6
Transferred out 4.0 0.9–7.1 1.6 0.2–2.9 2.6 0.9–4.2
Unknown outcome 0.7 0.0–1.5 13.4 11.2–15.6 8.0 2.6–13.4
https://doi.org/10.1371/journal.pone.0198916.t002
Table 3. Attrition rate by type of facility (PY = 17,068).
Outcome EPTS facilities
(Person-Years = 7539)
Non-EPTS facilities
(Person-Years = 9529)
Total
(Person-Years = 17068)
n n/100 PY 95% CI n n/100 PY 95% CI n n/100 PY 95% CI
Lost to follow-up 2568 33.4 28.1–39.7 4841 50.5 44.8–57.0 7409 42.9 35.1–52.5
Death 329 4.3 2.8–6.5 115 1.2 0.3–3.9 444 2.6 1.4–4.6
Total attrition 2897 37.7 31.8–44.8 4956 51.8 46.6–57.4 7853 45.5 38.5–53.8
https://doi.org/10.1371/journal.pone.0198916.t003
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associated with LTFU. Patients at smaller ART sites were 1.61 times more likely to be LTFU
(p = 0.088). Clinical stage, pregnancy, ART regimen, sex and CD4 count were all associated
with death. Stage IV patients were 3.8 times more likely and Stage III patients 2.1 times more
likely to have died than patients in Stage I. Non-pregnant patients were 3.2 times more at risk
than pregnant patients. Patients enrolled with 3TC+D4T+NVP had a 3.1 times higher proba-
bility and patients with regimens other than 3TC+TDF+EFV, 3TC+AZT+EFV, 3TC+AZT+
NVP or 3TC+D4T+NVP a 3.2 times higher probability to have died than patients enrolled
with 3TC+TDF+EFV. Male patients were 1.8 times more likely to die than female patients.
Patients with CD4150 were 3.0 times more at risk of dying than patients with CD4>300.
Discussion
This study is the first nationally representative study on ART retention and its predictors in
Mozambique, since the implementation of the national acceleration plan and the scaling up of
ART to more peripheral facilities [14]. The analysis clearly demonstrated that retention in antire-
troviral treatment was low overall. The 54% retention on ART at 12 months in our study is lower
than the global average of 74% and theWHO-recommended target of 85% [15]. The retention
rate was lower than what was routinely reported by PEPFAR-supported facilities. The facilities
that do not report retention through PEPFAR are all non-EPTS facilities, which had lower reten-
tion on treatment. They have on average a smaller number of people on ART, which was also
correlated with LTFU. Our study indicates a need to include all ART facilities in the routine
Table 4. Determinants of lost to follow-up (N = 15,750).
Characteristic Crude HR Adjusted HR 95% CI p-value
Clinical stage at ART initiation
Stage I/II/III - - - -
Stage IV 1.45 1.72 1.35–2.19 <0.001
CD4 count at ART initiation
151–400 - - - -
150 or less 1.27 1.28 1.07–1.52 0.007
More than 400 1.35 1.06 0.92–1.22 0.435
Pregnant at ART initiation
No - - - -
Yes 1.82 1.63 1.34–1.97 <0.001
Option B+
No - - - -
Yes 1.94 0.95 0.66–1.36 0.779
Participated in ART support group
Yes - - - -
No 8.81 7.09 1.28–39.16 0.025
Participated in ART support group
Yes - - - -
No 5.18 4.56 0.29–70.64 0.273
No on ART at the end of 2014
More than 1000 - - - -
Less than 1000 1.61 1.47 0.94–2.31 0.088
 Patients transferred out or of whom the outcome could not be ascertained with certainty were excluded. Patients who died are included.
 Excluding patients who were no longer active at 6 months.
https://doi.org/10.1371/journal.pone.0198916.t004
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monitoring of national retention rates, and not only those where data can easily be accessed.
This is best achieved by introducing an EPTS at as many ART facilities as possible [16].
Our national attrition rate estimate of 45.5/100 PY was slightly higher compared to the
results of a retrospective cohort study done in Central Mozambique in 2006–2008 [17] and
substantially higher than what was found in two other studies in 2002–2006 and 2005–2011,
respectively [18, 19]. These studies were however not nationally representative. A similar retro-
spective analysis of a nationally representative sample of 2,596 adults initiating ART at 58 facil-
ities in Mozambique was done during 2004–2007, before the expansion to more peripheral
facilities. It found that after one year 5% had died, 15% was lost to follow-up and 1% stopped
ART [20]. We observed a much higher LTFU rate and a lower death rate, which might indicate
that these changed over the last 10 years. An evaluation of outcome trends among adult ART
patients in Mozambique in the period 2004–2013 at 170 facilities with an EPTS, observed that
the 1-year LTFU rate increased during that period from 26% to 31% and the mortality declined
from 9% to 3%, supporting this conclusion [21]. Over that period, the patient population
began to include more female patients, a larger share of whom were pregnant, and to have a
higher baseline CD4 count. These three characteristics were negatively associated with death
in our analysis, providing a possible explanation for the lower mortality rate. An evidence-
based explanation for the increased LTFU rate is harder to find. The increase in the proportion
of pregnant women, who have a higher LTFU rate, is probably a contributing factor. It could
also be that as the number of people on ART at a facility increases, the more difficult it
Table 5. Determinants of deaths (N = 15,750).
Characteristic Crude HR Adjusted HR 95% CI p-value
Sex
Female - - - -
Male 2.86 1.83 1.50–2.22 <0.001
Clinical stage at ART initiation
Stage I - - - -
Stage II 1.72 1.12 0.81–1.57 0.485
Stage III 3.51 2.10 1.44–3.05 <0.001
Stage IV 7.18 3.82 2.50–5.83 <0.001
CD4 count at ART initiation
>300 - - - -
151–300 1.48 1.26 0.81–1.96 0.295
< = 150 3.59 3.01 1.84–4.91 <0.001
Pregnant at ART initiation
Yes - - - -
No 7.98 3.19 1.58–6.45 0.002
Option B+
Yes - - - -
No 13.4 1.95 0.29–12.95 0.481
ART Regimen at ART initiation
3TC+TDF+EFV - - - -
3TC+AZT+EFV 1.89 1.89 1.09–3.27 0.024
3TC+AZT+NVP 2.20 2.31 1.19–4.48 0.014
3TC+D4T+NVP 4.28 3.13 1.57–6.23 0.002
Other 4.88 3.24 1.74–6.02 <0.001
 Patients transferred out or of whom the outcome could not be ascertained with certainty were excluded
https://doi.org/10.1371/journal.pone.0198916.t005
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becomes to track defaulters. Another factor might be the further roll-out of ART to more
peripheral facilities where retention in care is more challenging. The number of people on
ART is foreseen to further increase with the implementation of the test-and-treat guidelines
[22], and extra attention on retention in care is indicated.
The attrition rate that we observed was higher than those found in most other sub-Saharan
African countries. Two systematic literature reviews of studies describing retention rates from
observational cohorts of adult ART patients in sub-Saharan Africa [3] and one review of one-
year retention amongst African children in ART [23], found substantially lower average attri-
tion rates than what we observed. This is consistent with an analysis of attrition rates that was
done in four countries (Kenya, Mozambique, Rwanda, and Tanzania) and concluded that
Mozambique had the highest attrition, for both adults and children [19, 24].
The clinical status of the patient at ART initiation, measured by the WHO clinical stage and
the CD4 count, has been associated with LTFU in other studies. Less healthy patients generally
have a higher risk of LTFU [18, 20, 21, 25–27]. This is likely to be partly due to undocumented
death among these patients [28]. Some studies found that LTFU also increased among patients
with a higher CD4 count [21, 29], but in our study the higher LTFU rate among patients with
CD4> = 400 disappeared after adjustment for other factors.
Of particular concern is LTFU among pregnant women that has shown to be a risk factor
in other studies [29, 30]. A previous study in Mozambique established that pregnant women
had, in the pre-ART period, a higher risk for LTFU [27] and also in the analysis of the treat-
ment outcome of adult ART patients in Mozambique in the period 2004–2013, pregnancy was
a risk factor [21]. Particularly, pregnant women enrolled under Option B+, and thus more
likely to be healthy, had in this analysis a higher attrition. In our analysis, we found that preg-
nant women had a much higher LTFU rate than non-pregnant patients, even after controlling
for age, sex, clinical stage and other factors. However, there was no significant difference in
LTFU rate between pregnant women recorded as initiating ART under Option B+ and other
pregnant women, making it uncertain to what extent the Option B+ program plays a role. We
observed that the classification of women as initiating treatment under Option B+ differed
across facilities, indicating possible misclassification, which could be the explanation for the
lack of difference. Retention in care among pregnant women needs to be strengthened, and
the effect of the Option B+ program on retention in care further investigated.
A particular interest of the study was to assess the effect of the ART adherence support
groups. Having participated in such a group was strongly negatively associated with LTFU.
The concept had, however, only recently been introduced and few (174) patients participated
in a support group. This substantially reduced the statistical power of our analysis. Patients
were only eligible to enrol in such a group when they had been active in care for at least 6
months. We therefore compared patients participating in support groups with other patients
who were still active at 6 months, and observed that the LTFU rate was still much higher
among non-support group patients (HR 4.56) but, because of the low numbers, the statistical
power was too low to rule out the possibility that this was merely due to chance. Also in the
study analysing the 2004–2013 EPTS data in Mozambique, participation in a support group
was associated with lower LTFU [21]. It is, however, possible that patients who accept to enrol
in the support groups are those that are already motivated to adhere to ART. As the program
continues to be rolled out, retention in care among patients participating in ART adherence
support groups needs to be closely monitored.
Risk factors for dying while in ART have not frequently been studied. The only socio-demo-
graphic that remained strongly associated with death, after adjusting for confounders, was gen-
der, with men having an almost double mortality rate than women. This is consistent with
what was found in some other studies [25, 31]. An obvious risk factor is the clinical status of
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the patient at ART initiation, as was documented by several other studies [21, 25, 29, 31, 32].
Both the WHO stage and the CD4 count were strongly and independently associated with
death. The higher death rate among patients with more advanced disease indicates a need to
improve early detection and enrolment in ART of patients with HIV.
We found a strong negative association between pregnancy at ART initiation and death,
similar to what has been documented by some other studies [21, 29]. This could be because
most pregnant women were enrolled under Option B+ and were therefore healthier, but even
after controlling for clinical stage and CD4 count, the association remained very strong. A pos-
sible explanation is that the available clinical information was insufficient to adequately control
for all clinical factors and that these factors caused residual confounding.
Finally, the ART regimen was strongly and independently associated with death. In particu-
lar regimens containing stavudine (D4T) had a higher mortality rate. The risk of stavudine has
previously been demonstrated in several other studies [21, 33, 34] andWHO therefore recom-
mends to phase it out [35]. Also in Mozambique stavudine has been replaced by AZT, but is
still used in certain therapeutic regimens such as when AZT causes severe anaemia or in young
children co-infected with TB. The presence of stavudine in these regimens could be an expla-
nation for the higher mortality, although that the worse clinical condition of patients using
these regimens also could. We did not collect all clinical data, such as for example the haemo-
globin status, and could therefore not control for it in our analysis.
The study design was an analysis of data retrospectively collected from routine health facil-
ity records and therefore suffers from the limitations inherent to this design. The recording of
routine data might not always be precise, which was confirmed by the inconsistencies found,
such as dates that do not follow a logical order, contradictory data in different fields, etc. Infor-
mation was often not filled out and many of the measured variables had a high proportion of
missing values. A particular challenge in our study was that it was not always possible to locate
and review all source documents. More specifically, at non-EPTS sites we could not access the
ARVmedicines refill card for 35% of patients. We could therefore not confirm with certainty
if patients who had not come for a consultation were lost to follow-up, or if these patients had
come to collect ARVs, without coming to consultation. Most of these patients (86%) were pa-
tients whose last consultation date was more than six months before the end of the 12-month
period, and for 68% more than nine months. The probability that these were patients that had
been LTFU was high and we therefore classified them as such. The remaining 14% had come
for consultation in the six months preceding the end of the 12-month period, and were pre-
sumed to have been patients still active in care. This has without doubt introduced a certain
level of misclassification, but we believe not to the extent that it invalidates our findings and
conclusions. The bias is most probably towards an underestimation of the attrition rate at
non-EPTS facilities. We considered all patients that had come for a consultation between 3
and 6 months before the end of the period as active in care, which might be too optimistic. The
difference in retention rate between EPTS and non-EPTS sites might thus be still higher than
what we estimated. The fact that it was so difficult to establish with certainty the outcome sta-
tus for so many patients on ART at facilities without EPTS is of concern. Improving patient
follow-up and outcome monitoring practices, for example by introducing EPTS, should be an
immediate priority. We collected data applying two different methods, extracting it from
EPTS databases and from paper-based recording tools, which reduces to some extent the com-
parison of EPTS sites with non-EPTS sites. We can, for example, not rule out the possibility
that the large difference found in characteristics such as being pregnant and being enrolled in
Option B+ is due to a different classification in the two systems.
An important limitation in assessing determinants of attrition is the fact that we only had
access to those characteristics available in the routine recording instruments. We don’t know
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about other factors that have shown to be related to attrition in the sub-Saharan African con-
text, such as patients’ socio-economic and educational level, distance living from ART facility,
mobility, providers’ attitudes, level of social support or home based care [4, 5, 22, 23, 24].
Some of these factors might be associated with our measured predictors, and thus be con-
founders. We can therefore not exclude that some of the established associations are in fact
caused by some of these other underlying factors.
Conclusion
Retention in antiretroviral therapy was very low in Mozambique in the study period, especially
among pregnant women and patients with a poor clinical condition at ART initiation, and it
should be improved. Facilities without EPTS, not included in the routine monitoring of reten-
tion, had a much lower retention rate and routine reporting should include these facilities. Early
detection and enrolment in care of people living with HIV needs to be increased to reduce the
number of deaths. Patients participating in ART adherence support groups present a promising
way forward, despite insignificance in this study due to a small sample. Adherence support needs
to be closely monitored to assess what the effect is as the support groups are being rolled out.
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